{"id":"dalteparin-fragmin","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Injection site hematoma"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL1201460","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated clotting factors, particularly factor Xa and to a lesser extent thrombin. This prevents thrombus formation and is used for thromboprophylaxis and treatment of thromboembolic disorders. It has a more predictable pharmacokinetic profile and longer half-life compared to unfractionated heparin.","oneSentence":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:57.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in patients undergoing abdominal surgery"},{"name":"Thromboprophylaxis in patients with restricted mobility during acute illness"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"},{"name":"Unstable angina and non-ST-segment elevation myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07494877","phase":"","title":"Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-09-01","conditions":"Infertility","enrollment":300},{"nctId":"NCT04790370","phase":"PHASE4","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-08-02","conditions":"Pulmonary Embolism","enrollment":544},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT06753786","phase":"NA","title":"Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-10-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage","enrollment":200},{"nctId":"NCT07461545","phase":"NA","title":"Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-02-04","conditions":"Cirrhosis, Splenectomy, Venous Thrombosis","enrollment":40},{"nctId":"NCT05672550","phase":"PHASE4","title":"Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-28","conditions":"Pediatric Kidney Transplant Recipients","enrollment":50},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT07464808","phase":"NA","title":"Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-28","conditions":"Venous Thromboembolic Event","enrollment":25},{"nctId":"NCT07462182","phase":"NA","title":"Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-04-01","conditions":"Intrauterine Growth Restriction","enrollment":108},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":"Venous Thromboembolism (VTE)","enrollment":2000},{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":"Venous Thromboembolism","enrollment":179},{"nctId":"NCT03041805","phase":"","title":"Caprini Score in Venous Surgery: a Prospective Cohort Study","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-01-01","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":3000},{"nctId":"NCT03728166","phase":"NA","title":"Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-02-01","conditions":"Venous Thromboembolism","enrollment":400},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum","enrollment":9200},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":"Acute Myocardial Infarction","enrollment":90},{"nctId":"NCT07388420","phase":"NA","title":"Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-02","conditions":"Hypertriglyceridemia Induced Acute Pancreatitis","enrollment":40},{"nctId":"NCT07388056","phase":"","title":"Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2012-01-01","conditions":"Cancer-associated Thrombosis","enrollment":169},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT07384013","phase":"NA","title":"Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2025-11-01","conditions":"Oncologic Diseases, Coagulation Defect, Pain Management","enrollment":30},{"nctId":"NCT06243510","phase":"NA","title":"Comparison of Apixaban Versus Enoxaparin","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-11-24","conditions":"Bladder Cancer","enrollment":90},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07365670","phase":"NA","title":"Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2026-04-01","conditions":"Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity","enrollment":22},{"nctId":"NCT06382584","phase":"","title":"Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-01-01","conditions":"Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery","enrollment":610},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":"Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia","enrollment":100},{"nctId":"NCT06315530","phase":"PHASE2","title":"Effect of Telitacicept on Antibody Titers in Primary APS Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2023-12-01","conditions":"Antiphospholipid Syndrome (APS)","enrollment":20},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT04273607","phase":"PHASE2, PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":40},{"nctId":"NCT07124819","phase":"PHASE3","title":"Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Avexima Diol LLC","startDate":"2024-07-22","conditions":"Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE)","enrollment":215},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":"Extracorporeal Circulation of Blood; Thrombocytopenia","enrollment":61},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT07342127","phase":"","title":"Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy","enrollment":100},{"nctId":"NCT05569681","phase":"NA","title":"Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients","status":"RECRUITING","sponsor":"Hawler Medical University","startDate":"2023-01-07","conditions":"Morbid Obesity","enrollment":2400},{"nctId":"NCT07330661","phase":"NA","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-01-01","conditions":"Deep Vein Thrombosis (DVT)","enrollment":1286},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT06937372","phase":"NA","title":"Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-08-01","conditions":"Hip Fractures, Venous Thromboembolism (VTE)","enrollment":21194},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT07302620","phase":"","title":"HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-12-03","conditions":"Thromboembolic Disease","enrollment":70},{"nctId":"NCT05171075","phase":"PHASE3","title":"A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2022-09-27","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism","enrollment":417},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT06628778","phase":"PHASE3","title":"Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2026-10-31","conditions":"Venous Thromboembolism (VTE)","enrollment":802},{"nctId":"NCT06329921","phase":"NA","title":"Inpatient Monitoring of Unfractionated Heparin","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-26","conditions":"Blood Clot, Thrombosis","enrollment":2000},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07183605","phase":"NA","title":"Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-09-22","conditions":"Anticoagulants and Bleeding Disorders","enrollment":30},{"nctId":"NCT02855047","phase":"","title":"The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2005-07","conditions":"Antiphospholipid Syndrome","enrollment":513},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT01588171","phase":"NA","title":"Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-05","conditions":"Venous Thromboembolic Diseases","enrollment":7020},{"nctId":"NCT05684796","phase":"NA","title":"Comparison of Two Pulmonary Embolism Treatments","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2023-11-27","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT05203705","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty","status":"TERMINATED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2022-03-07","conditions":"Prevention of Venous Thrombosis After TKA","enrollment":64},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04861103","phase":"PHASE4","title":"Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-10-01","conditions":"Pregnancy, High Risk, Anticoagulants","enrollment":12},{"nctId":"NCT05643885","phase":"","title":"A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Thromboembolism","enrollment":7304},{"nctId":"NCT07213713","phase":"","title":"Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Venous Thromboembolism, Obese Patients","enrollment":80},{"nctId":"NCT07189897","phase":"PHASE4","title":"Apixaban or Enoxaparin After Head and Neck Cancer Surgery","status":"RECRUITING","sponsor":"Kiranya Arnold","startDate":"2025-10","conditions":"Venous Thromboembolism, Head and Neck Cancer","enrollment":76},{"nctId":"NCT07195955","phase":"NA","title":"Cold Spray for Pain and Ecchymosis After Anticoagulant Prophylaxis in Orthopedic Surgery","status":"COMPLETED","sponsor":"Kocaeli University","startDate":"2024-02-01","conditions":"Nursing Care, Cold Application, Pain","enrollment":101},{"nctId":"NCT03244020","phase":"PHASE4","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2018-02-16","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":2868},{"nctId":"NCT07200674","phase":"","title":"Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-11","conditions":"Hypertriglyceridemia","enrollment":150},{"nctId":"NCT06180889","phase":"PHASE2","title":"Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2023-12-20","conditions":"Knee Arthroplasty, Total","enrollment":241},{"nctId":"NCT07168005","phase":"NA","title":"Informative Video Before LMWH Postpartum - Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum Care, Anxiety","enrollment":160},{"nctId":"NCT06776159","phase":"NA","title":"The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2025-06-24","conditions":"CVD - Cardiovascular Disease, Bruise, Pain","enrollment":180},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT06118957","phase":"PHASE2","title":"Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-10-11","conditions":"Thromboembolism","enrollment":64},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT06913595","phase":"PHASE1","title":"Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-03-25","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT05625932","phase":"PHASE3","title":"TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2023-03-02","conditions":"Colorectal Cancer Metastatic, Thromboembolism","enrollment":232},{"nctId":"NCT05576766","phase":"NA","title":"Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-09","conditions":"Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol","enrollment":54},{"nctId":"NCT07132515","phase":"PHASE4","title":"Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-08-15","conditions":"Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04762992","phase":"PHASE3","title":"LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)","status":"ENROLLING_BY_INVITATION","sponsor":"Centro Hospitalar de Lisboa Central","startDate":"2022-07-18","conditions":"Fetal Growth Retardation, Prematurity, Pre-Eclampsia","enrollment":12},{"nctId":"NCT02066454","phase":"PHASE3","title":"Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2014-06-05","conditions":"Myeloma, Venous Thromboembolism","enrollment":108},{"nctId":"NCT06484231","phase":"","title":"Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography","status":"COMPLETED","sponsor":"Ege University","startDate":"2023-07-24","conditions":"Malignancy","enrollment":25},{"nctId":"NCT06991530","phase":"","title":"Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure","status":"COMPLETED","sponsor":"The Second Hospital of Shandong University","startDate":"2021-01-01","conditions":"Low Molecular Weight Heparin, Recurrent Implantation Failure, FET","enrollment":392},{"nctId":"NCT07116239","phase":"NA","title":"Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-09","conditions":"Nephrotic Syndrome, Hypoalbuminemia","enrollment":60},{"nctId":"NCT05554055","phase":"","title":"Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-11","conditions":"Aortic Diseases, Arterial Disease, Thrombosis","enrollment":""},{"nctId":"NCT06004674","phase":"PHASE2","title":"Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-26","conditions":"Adverse Pregnancy Outcome","enrollment":20},{"nctId":"NCT06712004","phase":"PHASE2","title":"A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-02-10","conditions":"Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction","enrollment":40},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT06480994","phase":"","title":"Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support","status":"RECRUITING","sponsor":"Diagnostica Stago R&D","startDate":"2022-06-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1836},{"nctId":"NCT03045406","phase":"PHASE3","title":"Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2017-04-13","conditions":"Venous Thromboembolism","enrollment":1170},{"nctId":"NCT06875518","phase":"NA","title":"Comparative Study of Blood Loss in Total Laparoscopic Hysterectomy by Ligation the Uterine Arteries in Different Techniques.","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-03-12","conditions":"Gynecologic Disease","enrollment":60},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT04504318","phase":"PHASE1, PHASE2","title":"Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-12","conditions":"Venous Thromboembolism","enrollment":82},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT02887820","phase":"NA","title":"Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)","status":"TERMINATED","sponsor":"Stephen Esper","startDate":"2017-12-15","conditions":"Heart Disease, Lung Disease","enrollment":15},{"nctId":"NCT04741464","phase":"NA","title":"Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-02-02","conditions":"Deep Vein Thrombosis, Inflammatory Response","enrollment":9},{"nctId":"NCT05634057","phase":"NA","title":"Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis","status":"RECRUITING","sponsor":"Chen Ying","startDate":"2024-01-25","conditions":"Sepsis","enrollment":782},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT04536272","phase":"PHASE3","title":"Reduced Anticoagulation Targets in ECLS (RATE)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-10-01","conditions":"Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation","enrollment":330},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT06689241","phase":"NA","title":"Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":162},{"nctId":"NCT00203970","phase":"","title":"Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2001-02","conditions":"Thrombosis","enrollment":645}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABNORMAL BEHAVIOUR"},{"count":1,"reaction":"BLOOD TRIGLYCERIDES INCREASED"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"DECREASED EYE CONTACT"},{"count":1,"reaction":"DELUSION"},{"count":1,"reaction":"DEVICE RELATED INFECTION"},{"count":1,"reaction":"DISORIENTATION"},{"count":1,"reaction":"ELECTROCARDIOGRAM QT PROLONGED"},{"count":1,"reaction":"ENCEPHALOPATHY"},{"count":1,"reaction":"FEELING HOT"}],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dalteparin (Fragmin)","genericName":"Dalteparin (Fragmin)","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalteparin, also known as Fragmin, is an oligosaccharide antithrombin-III activator used to treat various conditions, including venous thromboembolism and pulmonary thromboembolisms. It is administered subcutaneously, either through traditional injections or via once-weekly subcutaneous ports, and its effectiveness can be monitored through point-of-care testing methods such as anti-Xa activity point-of-care testing.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}